Ashland Inc. filed its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission on November 20, 2026, covering the fiscal year ended September 30, 2026.

Key Highlights

  • Shares outstanding: As of October 31, 2026, Ashland reported 45,833,893 shares of Common Stock outstanding.
  • Market capitalization of float: As of March 31, 2026, the aggregate market value of common stock held by non-affiliates was approximately $2.5 billion, based on the closing price on the New York Stock Exchange.
  • Four reportable segments: The company disclosed four reportable operating segments: Life Sciences, Personal Care, Specialty Additives, and Intermediates.
  • Recent divestitures: According to the filing, the nutraceuticals business was sold in August 2024 and the Avoca business was sold in March 2025.
  • Global workforce: The company disclosed approximately 2,800 employees worldwide, serving customers in more than 100 countries.
  • Large accelerated filer status: The registrant indicated it qualifies as a large accelerated filer under the Exchange Act definitions.

Ashland's Fiscal 2026 Annual Disclosure: Segments, Divestitures, and Global Footprint

Ashland Inc. (NYSE:ASH), a Delaware corporation headquartered at 8145 Blazer Drive, Wilmington, Delaware, described itself in the filing as "a global additives and specialty ingredients company with a conscious and proactive mindset for sustainability." The company serves customers across architectural coatings, construction, energy, food and beverage, personal care, and pharmaceutical markets, according to the 10-K.

The filing outlines four reportable operating segments. Life Sciences covers pharmaceuticals, nutrition, and agricultural chemicals, supplying controlled release polymers, tablet coatings, bioprocessing chemicals, thickeners, and specialty polymers. Personal Care provides biofunctionals, skin care, hair care, oral care, and household solutions, with an emphasis on nature-derived and biodegradable ingredients for large multinational and boutique consumer products companies. Specialty Additives serves architectural coatings, construction, energy, automotive, and industrial markets with rheology modifiers, foam control agents, surfactants, and related materials. Intermediates focuses on the production of 1,4 butanediol ("BDO") and related derivatives including n-methylpyrrolidone, used as chemical intermediates and specialty process solvents.

The company noted two completed divestitures within the reporting period: the nutraceuticals business, sold in August 2024, and the Avoca business, sold in March 2025. The 10-K also states that portions of the registrant's proxy statement for its 2027 Annual Meeting of Stockholders are incorporated by reference into Part III of the Form 10-K. The filing confirms the company is not a shell company and has met all required electronic submission obligations under Rule 405 of Regulation S-T.

What Was Disclosed

Ashland Inc. filed its fiscal year 2026 Form 10-K reporting 45,833,893 shares outstanding as of October 31, 2026, an approximate $2.5 billion non-affiliate market value as of March 31, 2026, four operating segments, and two completed business divestitures.